Cephalon Receives FDA Approval of REMS for GABITRIL

Cephalon, Inc. announced that a Risk Evaluation and Mitigation Strategy (REMS) for its antiepileptic medication GABITRIL (tiagabine hydrochloride) has been approved.
KansasCity